The full name

email@vos.com

Manage profile
Sign Out
Sign In

º Oncology

Cancer Organoid Based Drug Efficacy Testing Service
The oncology drug efficacy evaluation platform is based on patient-derived organoids (PDOs).
This advanced platform enables the evaluation of oncology agents and immunotherapeutics by utilizing a co-culture system incorporating immune cells from the tumor microenvironment.

Next-Generation Anti-Cancer Drug Development & Efficacy Evaluation with Patient-Derived Organoids (PDOs)

High-Fidelity Preclinical Models
Oncology utilizes 3D patient-derived organoids (PDOs) cultured directly from tumor biopsies.
These models preserve the original tumor’s genetic and phenotypic characteristics, providing a more clinically relevant system than traditional 2D cell lines or animal models.
High-Fidelity Preclinical Models
A comprehensive biobank of PDOs, derived from a wide range of cancer types, forms an expansive repository that supports robust screening efforts.
This resource enables the identification of drug candidates across diverse tumor profiles and informs strategic decision-making throughout the R&D pipeline.

Cancer Organoid

Endometrial Cancer Organoid

Cancer Organoid

Endometrial Cancer Organoid

1784€+

Hepatocarcinoma Cancer Organoid

Cancer Organoid

Hepatocarcinoma Cancer Organoid

1784€+

Ovarian Cancer Organoid

Cancer Organoid

Ovarian Cancer Organoid

1784€+

Gastric Cancer Organoid

Cancer Organoid

Gastric Cancer Organoid

1784€+

Pancreatic Cancer Organoid

Cancer Organoid

Pancreatic Cancer Organoid

1784€+

Non-Small Cell Lung Cancer Organoid

Cancer Organoid

Non-Small Cell Lung Cancer Organoid

1784€+

Colorectal Cancer Organoid

Cancer Organoid

Colorectal Cancer Organoid

1784€+

Cholangiocarcinoma Organoid

Cancer Organoid

Cholangiocarcinoma Organoid

1784€+

Breast Cancer Organoid

Cancer Organoid

Breast Cancer Organoid

1787€+

Tumor Microenvironment

Cancer Associate Fibroblast (CAF)

Tumor Microenvironment

Cancer Associate Fibroblast (CAF)

2425€+

Cytotoxic T cell

Tumor Microenvironment

Cytotoxic T cell

6003€+

Tumor-Infiltrating Lymphocyte

Tumor Microenvironment

Tumor-Infiltrating Lymphocyte

9057€+

Regulatory T cell

Tumor Microenvironment

Regulatory T cell

7500€+

Macrophage

Tumor Microenvironment

Macrophage

7500€+

Organoid Establishment and Banking for 12 cancer types

Established Cancer Organoid
Available pre-clinical research
  • Donor-matched immune microenvironment
  • Various patient-derived organoid lineups
  • High-resolution data (HCS, FACS, NGS, scRNAseq, multiflex IHC)
  • Fully customized service
Available clinical data
  • Basic clinical data
  • Drug sensitivity prediction
  • Patient follow-up data
  • Clinical bioinformatics (NGS, RNAseq, Spatial biology)

Validation Complete for cancer organoid

  • Clinical information
  • Drug sensitivity test
  • Genetic mutation (WES analysis)
  • Specific cancer marker expression (Immunohistochemistry, Multiflex)
WES analysis in pancreatic cancer organoid
Drug sensitivity test in pancreatic cancer organoid

Enhance clinical predictive accuracy by developing advanced in vitro models that more accurately recapitulate the Tumor Microenvironment (TME)

Immune-Microenvironment with Cytotoxic T cells
Immune checkpoint determine whether cancer cells are killed after TCR-MHC binding
Immune checkpoint determine whether cancer cells are killed after TCR-MHC binding

Why Lambda?

Solutions

Insights

Contact us

Lambda Biologics

Lambda Biologics GmbH

Contact

info@lambdabiologics.com

Deutscher Platz 5c
04103, Leipzig
Germany
© 2025 Lambda Biologics GmBH. All Rights Reserved.

Connect with Us

By submitting your details, you confirm that you have reviewed and agree with the Lambda Biologics Privacy Policy.